A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Type 2 Diabetes MellitusChronic Kidney Disease
Interventions
BIOLOGICAL

Renal Autologous Cell Therapy (REACT)

Autologous selected renal cells (SRC).

PROCEDURE

Renal Biopsy

a procedure in which a small sample of kidney tissue is removed

Trial Locations (16)

18103

Lehigh Valley Health Network, Allentown

27599

University of North Carolina- Chapel Hill, Chapel Hill

32610

University of Florida, Gainesville

37212

Vanderbilt University, Nashville

38801

Nephrology & Hypertension Associates, Tupelo

40202

University of Louisville, Louisville

45246

Mt. Sinai Hospital, New York

48109

University of Michigan, Ann Arbor

49007

Paragon Health, Kalamazoo

53705

University of Wisconsin-Madison, Madison

60637

University of Chicago Medical Center, Chicago

70808

Renal Associates of Baton Rouge, Baton Rouge

80210

Kidney Associates of Colorado, Denver

83642

Boise Kidney and Hypertension Institute, Meridian

85724

University of Arizona, Tucson

06520

Yale Univeristy, New Haven

Sponsors
All Listed Sponsors
collaborator

CTI Clinical Trial and Consulting Services

OTHER

lead

Prokidney

INDUSTRY